Itepekimab, CAS 2226742-52-3

Product Description: Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD)[1][2][3][4].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Wechsler ME, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668./[2]Kosloski MP, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-395./[3]Rabe KF, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-1298.

CAS Number: 2226742-52-3

Molecular Weight: N/A

Compound Purity: 95.0

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Interleukin Related;NF-κB

• Artikelnummer: MEXHY-P99673-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99673-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated